阿尔茨海默病中的替代拼接:机制,治疗含义和3D建模方法
Matthew Pasteris1, Senem Cakir1, Anna Bellizzi1
1Department of Microbiology, Immunology and Inflammation, Center for Neurovirology and Gene Editing, Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA.
Journal of Alzheimer's disease : JAD
|July 21, 2025
概括
粉样β前体蛋白 (AβPP) 的替代拼接产生影响阿尔茨海默病 (AD) 病理学的异型. 本综述探讨了APP拼接,它在Aβ产生中的作用以及神经退行性疾病的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 阿尔茨海默病 (AD) 涉及粉样β (Aβ) 斑块和神经纤维细胞结.
- 粉样β前体蛋白 (AβPP) 的裂变会产生神经毒性Aβ.
- AβPP和tau (MAPT) 替代拼接 (AS) 影响蛋白质功能和神经退行.
研究的目的:
- 审查APP替代拼接在阿尔茨海默病和神经退行性疾病中的作用.
- 探索APP异形调节如何影响Aβ的生产.
- 讨论针对神经退行和AD的拼接失调的新疗法.
主要方法:
- 文献审查侧重于APP替代拼接.
- 分析APP异型体对Aβ生产的影响.
- 讨论治疗策略和3D培养模型,用于研究神经退行症中的拼接.
主要成果:
- APP前mRNA的替代拼接产生了具有不同功能的独特异型.
- APP拼接失调与阿尔茨海默病的发病有关.
- 针对异常拼接,为神经退行性疾病提供了潜在的治疗途径.
结论:
- 在AD中,APP替代拼接是AβPP功能和Aβ生产的关键调节器.
- 了解APP拼接机制对于开发有效的AD疗法至关重要.
- 三维培养模型为研究神经退行症的拼接提供了一个有前途的平台.
相关概念视频
Alternative RNA Splicing
21.7K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
21.7K
RNA Splicing
57.1K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
57.1K
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669


